Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;53(6):605-11.
doi: 10.3325/cmj.2012.53.605.

Electrophysiological predictors of propafenone efficacy in prevention of atrioventricular nodal re-entrant and atrioventricular re-entrant tachycardia

Hrvoje Pintarić  1 , Ivan Zeljković, Zdravko Babić, Mislav Vrsalović, Nikola Pavlović, Hrvojka Bosnjak, Dubravko Petrac
Affiliations

Electrophysiological predictors of propafenone efficacy in prevention of atrioventricular nodal re-entrant and atrioventricular re-entrant tachycardia

Hrvoje Pintarić et al. Croat Med J. 2012 Dec.

Abstract

Aim: To assess the efficacy of propafenone in prevention of atrioventricular nodal reentrant tachycardia (AVNRT) and orthodromic atrioventricular tachycardia (AVRT) based on the clinical results of arrhythmia recurrence and find the electrophysiological predictor of propafenone effectiveness.

Methods: This retrospective study included 44 participants in a 12-month period, who were divided in two groups: group A - in which propafenone caused complete ventriculo-atrial block and group B - in which propafenone did not cause complete ventriculo-atrial block.

Results: Group A had significantly lower incidence of tachycardia than group B (95% vs 70.8%, P=0.038), and complete ventriculo-atrial block predicted the efficacy of propafenone oral therapy in the prevention of tachycardia (sensitivity 87.5%, specificity 52.8%, positive predictive value 95%, negative predictive value 29.2%). Patients with AVNRT in group B who did not experience the recurrences of tachycardia had significantly shorter echo zone before intravenous administration of propafenone than the patients who experienced episodes of sustained tachycardia (median 40 ms [range 15-60 ms] vs 79 ms [range 50-180 ms], P=0.008).

Conclusion: In patients with non-inducible tachycardia, complete ventriculo-atrial block can be used as an electrophysiological predictor of the efficacy of propafenone oral therapy in the prevention of tachycardia. In patients with non-inducible AVNRT, but without complete ventriculo-atrial block, propafenone was more effective in patients with shorter echo zone of tachycardia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sorbera C, Cohen M, Woolfe P, Kalapatapu SR. Atrioventricular nodal reentry tachycardia: Slow pathway ablation using the transseptal approach. Pacing Clin Electrophysiol. 2000;23:1281–4. doi: 10.1111/j.1540-8159.2000.tb00961.x. - DOI - PubMed
    1. Altemose GT, Scott LR, Miller JM. Atrioventricular node reentrant tachycardia requiring ablation of the mitral annulus. J Cardiovasc Electrophysiol. 2000;11:1281–95. doi: 10.1046/j.1540-8167.2000.01281.x. - DOI - PubMed
    1. Iyer R, Hameed S, Vora AM, Lokhandwala Y. Radiofrequency ablation: a cure for tachyarrhythmias. J Indian Med Assoc. 2000;98:684–7. - PubMed
    1. Feldman A, Voskoboinik A, Kumar S, Spence S, Morton JB, Kistler PM, et al. Predictors of acute and long-term success of slow pathway ablation for atrioventricular nodal reentrant tachycardia: a single center series of 1,419 consecutive patients. Pacing Clin Electrophysiol. 2011;34:927–33. doi: 10.1111/j.1540-8159.2011.03092.x. - DOI - PubMed
    1. Wyse DG, Talajic M, Hafley GE, Buxton AE, Mitchell LB, Kus TK, et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT). Drug testing and as-treated analysis. J Am Coll Cardiol. 2001;38:344–51. doi: 10.1016/S0735-1097(01)01402-4. - DOI - PubMed

MeSH terms